Market Checkup: A Biotech Buyout and Another Big Pharma Scandal Brewing in China?
In this edition of Market Checkup, health-care analysts David Williamson and Max Macaluso discuss today's biggest health-care news, including Amgen's multibillion-dollar acquisition of oncology specialist Onyx Pharmaceuticals, Rigel Pharmaceuticals' latest clinical trial disappointment, new allegations of a big pharma's misconduct in China, and a new opportunity in Eli Lilly's animal health division.
It's no secret that biotech stocks like Amgen and Onyx have been soaring recently, but let's face it --- the best investment strategy is to pick great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" not only shares stocks that could help you build long-term wealth, but also winning strategies that every investor should know. Click here to get your free copy today.
The article Market Checkup: A Biotech Buyout and Another Big Pharma Scandal Brewing in China? originally appeared on Fool.com.David Williamson owns shares of Pfizer. Max Macaluso, Ph.D. owns shares of Celgene. The Motley Fool recommends Celgene. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.